会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明申请
    • Method of treating diabetes by inhibiting degradation of at least one of crebl1, atf6, and hnf-4 alpha by htra
    • 通过抑制htra中crebl1,atf6和hnf-4α中的至少一种降解来治疗糖尿病的方法
    • US20070196354A1
    • 2007-08-23
    • US10563073
    • 2004-09-30
    • Hirofumi DoiKen Saito
    • Hirofumi DoiKen Saito
    • A61K38/48C12Q1/37
    • A61K45/06
    • The present invention found the interaction of CREBL1 and HNF-4α with HtrA2 and revealed for the first time that CREBL1, ATF6, and HNF-4α are degraded by active HtrA2. In addition, the present invention provides a means for inhibiting the degradation of at least one of CREBL1, ATF6, and HNF-4α, comprising inhibiting the function of HtrA2; a means for preventing and/or treating diabetes, comprising inhibiting the degradation by HtrA2 of at least one of CREBL1, ATF6, and HNF-4α; a means for preventing cell death (for example, pancreatic β cell death), comprising inhibiting the degradation by HtrA2 of CREBL1 and/or ATF6; a means for preventing and/or treating type 2 diabetes, comprising inhibiting the degradation by HtrA2 of HNF-4α; and a reagent kit.
    • 本发明发现CREBL1和HNF-4α与HtrA2的相互作用,首次发现CREBL1,ATF6和HNF-4α被活性HtrA2降解。 此外,本发明提供了抑制CREBL1,ATF6和HNF-4α中的至少一种降解的方法,包括抑制HtrA2的功能; 用于预防和/或治疗糖尿病的方法,包括抑制HtrA2对CREBL1,ATF6和HNF-4α中的至少一种的降解; 一种预防细胞死亡(例如胰腺β细胞死亡)的方法,包括抑制HtrA2对CREBL1和/或ATF6的降解; 用于预防和/或治疗2型糖尿病的方法,包括抑制HtrA2对HNF-4α的降解; 和试剂盒。
    • 42. 发明申请
    • Method of degrading transcriptional factors of saccharometabolism-associated gene, method for inhibiting the degradation, and agent for inhibiting degradation and degradation inhibitor
    • 降低糖代谢相关基因转录因子的方法,抑制降解的方法和抑制降解抑制剂
    • US20070004636A1
    • 2007-01-04
    • US10526234
    • 2003-08-29
    • Hirofumi DoiGen Kudo
    • Hirofumi DoiGen Kudo
    • C12Q1/37A61K38/05A61K38/04C07K5/06C07K5/04
    • C07K7/06A61K38/00C07K5/06043C07K5/06191C12N9/6472
    • Based on the finding that m-calpain or μ-calpain degrades hepatocyte nuclear factor 4α (HNF-4α), hepatocyte nuclear factor 1α (HNF-1α) and insulin promoter factor 1 (IPF-1), which form transcription factor networks involved in expression of glucose metabolism-related genes in pancreatic β cells, the following have been provided: a method for degradation of these transcription factors; a method for inhibiting the degradation and an agent for inhibiting the degradation; a method for enhancing production of the gene product of a gene on which these factors act as transcription factors and an agent for enhancing the same; an agent for preventing and/or treating a disease attributable to the degradation of these transcription factors and a method for preventing and/or treating the disease; a method for identifying a compound that inhibits the degradation of these transcription factors by calpain; a compound obtained by the identification method; and a reagent kit including calpain, these transcription factors, polynucleotides encoding these factors, and a vector containing the polynucleotides.
    • 基于m-calpain或mu-calpain降解肝细胞核因子4α(HNF-4alpha),肝细胞核因子1alpha(HNF-1alpha)和胰岛素启动子因子1(IPF-1)的发现,其形成转录因子网络 葡萄糖代谢相关基因在胰腺β细胞中的表达已经提供:一种降解这些转录因子的方法; 抑制降解的方法和抑制降解的试剂; 用于增强这些因子作为转录因子的基因的基因产物的产生的方法和用于增强其的药剂; 用于预防和/或治疗可归因于这些转录因子降解的疾病的药剂和预防和/或治疗疾病的方法; 用于鉴定通过钙蛋白酶抑制这些转录因子降解的化合物的方法; 通过鉴定方法获得的化合物; 以及包含钙蛋白酶,这些转录因子,编码这些因子的多核苷酸以及含有多核苷酸的载体的试剂盒。
    • 43. 发明申请
    • Method of controlling transcription insulin gene
    • 控制转录胰岛素基因的方法
    • US20060276387A1
    • 2006-12-07
    • US10544061
    • 2004-11-26
    • Hirofumi DoiKensaku ImaiNaoya Wada
    • Hirofumi DoiKensaku ImaiNaoya Wada
    • A61K38/22C12Q1/68G01N33/53
    • C07K14/62G01N33/74G01N2500/02
    • A method for promoting insulin gene transcription, which comprises the step of inhibiting binding of IPF1 and any one of proteins selected from the following group: (i) HNF3G, (ii) PHF1, and (iii) DLX4; and a method for screening a substance that promotes insulin gene transcription, which comprises the step of bringing a test substance into contact with IPF1 and/or any one of proteins selected from the following group under a condition that allows the binding of IPF1 and said protein and then determining whether or not the test substance inhibits the binding of IPF1 and said protein by detecting presence or absence, or change of a signal and/or a marker generated by the binding of IPF1 and said protein in a system in which the signal and/or the marker can be detected: (i) HNF3G, (ii) PHF1, and (iii) DLX4.
    • 一种促进胰岛素基因转录的方法,其包括抑制IPF1与选自以下组中的任何一种蛋白质结合的步骤:(i)HNF3G,(ii)PHF1和(iii)DLX4; 以及用于筛选促进胰岛素基因转录的物质的方法,其包括在允许IPF1和所述蛋白质结合的条件下使测试物质与IPF1和/或选自以下组的任何一种蛋白质接触的步骤 然后通过检测存在或不存在检测物质来抑制IPF1和所述蛋白质的结合,或者通过IPF1和所述蛋白质的结合产生的信号和/或标记的变化来抑制IPF1和所述蛋白质的结合,其中信号和 /或可以检测标记:(i)HNF3G,(ii)PHF1和(iii)DLX4。